| A.4. Individual Results of the Methodology Quality Questionnaire (Recoded Results) Methodology Quality Questionnaire | Internal Validity Questions (IV) | External Validity Questions (IV) | Statistical Validity Questions (SV) | ||||||||||||||||||||
| Author(s) | Year | Control group | X1 | X2 | X3 | X4 | X5 | X6 | X7 | IVS* | X8 | X9 | X10 | X11 | X12 | EVS* | X13 | X14 | X15 | X16 | X17 | SVS* | MQS |
| Vetel JM (multidose) | 1991 | Placebo | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.43 | 1 | 0 | 0 | 1 | 0 | 0.20 | 1 | 0 | 1 | 1 | 1 | 0.40 | 0.34 |
| Baumer P | 1992 | Placebo | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.43 | 1 | 0 | 0 | 1 | 0 | 0.20 | 1 | 0 | 1 | 1 | 1 | 0.40 | 0.34 |
| Rogé J | 1993 | Loperamide | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0.36 | 1 | 0 | 0 | 0 | 0 | 0.10 | 0 | 0 | 0 | 1 | 1 | 0.20 | 0.22 |
| Frexinox J | 1996 | Loperamide oxide | 1 | 0 | 0 | 1 | 1 | 1 | 0 | 0.29 | 1 | 0 | 0 | 1 | 0 | 0.20 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.16 |
| Hamza H | 1999 | Placebo | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0.36 | 1 | 1 | 1 | 1 | 0 | 0.40 | 1 | 1 | 0 | 1 | 1 | 0.40 | 0.39 |
| Vetel JM | 1999 | Loperamide | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0.36 | 1 | 1 | 1 | 1 | 0 | 0.40 | 1 | 1 | 1 | 1 | 1 | 0.50 | 0.42 |
| Lin Sanren | 2000 | Loperamide | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0.21 | 1 | 1 | 1 | 1 | 0 | 0.40 | 1 | 0 | 0 | 0 | 1 | 0.20 | 0.27 |
| Coulden S | 2001 | Loperamide | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0.14 | 1 | 1 | 1 | 1 | 0 | 0.40 | 1 | 0 | 0 | 1 | 1 | 0.30 | 0.28 |
| Moraes E | 2001 | Saccharomyces boulardii | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0.07 | 1 | 1 | 1 | 1 | 0 | 0.40 | 1 | 1 | 1 | 1 | 1 | 0.50 | 0.32 |
| Prado D | 2002 | Loperamide | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0.14 | 1 | 1 | 1 | 1 | 0 | 0.40 | 1 | 1 | 1 | 1 | 1 | 0.50 | 0.35 |
| Wang HH | 2005 | Loperamide | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0.21 | 1 | 1 | 1 | 1 | 0 | 0.40 | 1 | 0 | 0 | 1 | 1 | 0.30 | 0.30 |
| Coffin B | 2007 | Dexecadotril Placebo | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0.43 | 1 | 1 | 1 | 1 | 0 | 0.40 | 1 | 1 | 1 | 0 | 1 | 0.40 | 0.41 |
| Gallelli L | 2010 | Loperamide | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0.14 | 1 | 1 | 1 | 1 | 0 | 0.40 | 1 | 0 | 1 | 1 | 0 | 0.30 | 0.28 |
| Yao P | 2011 | Oral rehydration solution | 0 | 0 | 0 | 0 | 0 | 2 | ? | 0.14 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0 | 0 | 0 | 0 | 0 | 0.00 | 0.05 |
| Mehta S | 2012 | Placebo octreotide | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0.14 | 0 | 0 | 1 | 1 | 0 | 0.20 | 0 | 0 | 1 | 1 | 1 | 0.30 | 0.21 |
| Mean | 0.47 | 0.33 | 0.00 | 0.53 | 0.47 | 1.07 | 0.73 | 0.26 | 0.87 | 0.60 | 0.67 | 0.87 | 0.00 | 0.30 | 0.73 | 0.33 | 0.53 | 0.73 | 0.80 | 0.31 | 0.29 | ||
| SD | 0.5 | 0.47 | 0 | 0.50 | 0.50 | 0.25 | 0.41 | 0.12 | 0.34 | 0.49 | 0.47 | 0.34 | 0 | 0.13 | 0.44 | 0.47 | 0.50 | 0.44 | 0.40 | 0.15 | 0.10 | ||